Related Experiment Videos
Pharmacokinetics of cimetidine in critically ill children
Insights
Cimetidine (an H2 blocker) pharmacokinetics in critically ill children show faster clearance and larger distribution volume than adults. A starting dose of 24 mg/kg daily is suggested for pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Critical Care
- Drug Metabolism
Background:
- Cimetidine pharmacokinetics are not well-established in pediatric populations.
- Lack of established pediatric dosing guidelines for cimetidine.
- Need for pharmacokinetic data in critically ill children to optimize therapy.
Purpose of the Study:
- To characterize the pharmacokinetic profile of cimetidine in critically ill children.
- To provide data to support the development of pediatric dosing guidelines for cimetidine.
- To compare cimetidine pharmacokinetics in children to adult data.
Main Methods:
- Single intravenous dose administration of cimetidine.
- Continuous infusion of cimetidine at three incremental rates.
- Pharmacokinetic parameter analysis including elimination half-life, clearance, and volume of distribution.
- Study conducted in critically ill pediatric patients.
Main Results:
- Mean elimination half-life of cimetidine was 1.44 +/- 0.41 hours.
- Pediatric patients exhibited faster cimetidine clearance (14.21 +/- 2.85 ml/min/kg) compared to adults.
- A larger apparent volume of distribution (2.13 +/- 0.63 l/kg) was observed in these children.
- Data gathered from intravenous dosing and continuous infusion.
Conclusions:
- Critically ill children demonstrate distinct cimetidine pharmacokinetic behavior compared to adults.
- A rational starting daily dose of 24 mg/kg for cimetidine in critically ill children is proposed.
- Further research may refine cimetidine dosing strategies in pediatric intensive care settings.
Abstract:
The pharmacokinetic behavior of cimetidine has not been described in children, and there is no authoritative guideline on cimetidine dosage for children. Cimetidine pharmacokinetics were studied after a single intravenous dose and during three, incremental rates of continuous infusion in critically ill children. The mean elimination half-life of cimetidine was 1.44 +/- 0.41 hours. Compared to adults, these children had a relatively faster clearance (14.21 +/- 2.85 ml/min/kg) of cimetidine and a larger apparent distribution volume (2.13 +/- 0.63 l/kg). Based on our results, it appears rational to initiate cimetidine at a daily dose of 24 mg/kg in critically ill children.